EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical Utility of ctDNA Analysis in Lung Cancer—A Review

Kamil Makar iD, Agata Wróbel, Adam Antczak, Damian Tworek iD

Advances in Respiratory Medicine · 12.06.2025 · 93 (3) · 17

DOI: 10.3390/arm93030017 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advances in Respiratory Medicine, online erschienen am 12.06.2025. Verfasst von Kamil Makar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of General and Oncological Pulmonology, Medical University of Lodz, Stefana Zeromskiego 113, 90-549 Lodz, Poland. Hauptthemen laut MEDLINE: Lung Neoplasms, Circulating Tumor DNA, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Circulating free DNA (cfDNA) is genetic material released from various cells into bodily fluids. Among its fractions, circulating tumor DNA (ctDNA) originates from tumor cells and reflects their genetic material, including mutations and epigenetic changes. Methods commonly employed for detecting ctDNA in blood include next-generation sequencing (NGS) and various types of PCR. The presence of ctDNA can be utilized in liquid biopsies for many diagnostic purposes related to various cancers. It is a minimally invasive method of sampling molecular compounds from tumor cells. In this paper, we focus on current knowledge regarding the liquid biopsy of blood ctDNA in the context of lung cancer, one of the leading causes of cancer-related mortality. Currently, as a clinically approved method, liquid biopsy serves as a complementary technique in NSCLC diagnostic and genetic profiling. Other applications of liquid biopsy that are still being investigated include the detection of minimal residual disease (MRD) after curative treatment and response monitoring to systemic treatment. This review discusses current and future potential directions for the development and implementation of ctDNA for patients with NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCirculating Tumor DNACarcinoma, Non-Small-Cell LungHumansLiquid BiopsyBiomarkers, TumorHigh-Throughput Nucleotide Sequencing

Stichwörter der Autor:innen

NSCLCcancer diagnosticscfDNActDNAliquid biopsylung cancer

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of General and Oncological Pulmonology, Medical University of Lodz, Stefana Zeromskiego 113, 90-549 Lodz, Poland.
  • Faculty of Medicine, Medical University of Lodz, Pomorska 251, 92-213 Lodz, Poland.

ORCID-Profile: Kamil Makar, Damian Tworek

Zitieren

APA

Makar, K., Wróbel, A., Antczak, A., & Tworek, D. (2025). Clinical Utility of ctDNA Analysis in Lung Cancer—A Review. Advances in Respiratory Medicine, 93(3), 17. https://doi.org/10.3390/arm93030017

Vancouver

Makar K, Wróbel A, Antczak A, Tworek D. Clinical Utility of ctDNA Analysis in Lung Cancer—A Review. Advances in Respiratory Medicine. 2025;93(3):17. doi:10.3390/arm93030017

BibTeX
@article{Makar2025,
  author = {Makar, Kamil and Wróbel, Agata and Antczak, Adam and Tworek, Damian},
  title = {Clinical Utility of ctDNA Analysis in Lung Cancer—A Review},
  journal = {Advances in Respiratory Medicine},
  year = {2025},
  volume = {93},
  number = {3},
  pages = {17},
  doi = {10.3390/arm93030017}
}
Kostenlos starten →